Newbury Pharmaceuticals AB (NEWBRY) - Total Liabilities
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has total liabilities worth Skr45.96 Million SEK (≈ $4.95 Million USD) as of February 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Newbury Pharmaceuticals AB (NEWBRY) equity growth momentum to track the company's year-over-year net asset growth rate.
Newbury Pharmaceuticals AB - Total Liabilities Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. See Newbury Pharmaceuticals AB (NEWBRY) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Newbury Pharmaceuticals AB Competitors by Total Liabilities
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dharma Samudera Fishing Tbk
JK:DSFI
|
Indonesia | Rp153.62 Billion |
|
Watta Holding Bhd
KLSE:7226
|
Malaysia | RM11.61 Million |
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
USA | $7.32 Million |
|
Chia Yi Steel Co Ltd
TWO:2067
|
Taiwan | NT$1.64 Billion |
|
Trailbreaker Resources Ltd
V:TBK
|
Canada | CA$268.94K |
|
Unibap AB
ST:UNIBAP
|
Sweden | Skr28.97 Million |
|
Auga Group AB
STU:W9Z
|
Germany | €172.99 Million |
|
WISDOM ED.INTL.HLD.HD-01
F:5Q4
|
Germany | €620.83 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Newbury Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Newbury Pharmaceuticals AB (NEWBRY) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Newbury Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual total liabilities of Newbury Pharmaceuticals AB from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-08-31 | Skr38.95 Million ≈ $4.19 Million |
+65.49% |
| 2023-08-31 | Skr23.54 Million ≈ $2.53 Million |
+29.79% |
| 2022-08-31 | Skr18.14 Million ≈ $1.95 Million |
+317.95% |
| 2021-08-31 | Skr4.34 Million ≈ $466.95K |
-- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.